Eli Lilly’s experimental obesity drug shows over 11% weight loss in early trial

Lilly’s experimental obesity drug shows promise in early study

By Madison Muller, Bloomberg News An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association confere…

Advice for trying GLP-1 drugs for weight loss from a doctor who's been there

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.

Eli Lilly’s obesity drug causes 11% weight loss (LLY:NYSE)

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Eli Lilly’s experimental obesity drug shows over 11% weight loss in early trial

(Reuters) -Eli Lilly’s experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on Friday. The 12-week result was published in an abstract ahead of the American Diabetes Association conference in Chicago, the brokerage said. Cantor analyst Prakhar Agrawal said the data on eloralintide looked strong in terms of weight l…

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.